Alfasigma and Fangzhou Discuss Future of Internet Healthcare in China
Alfasigma Group and Fangzhou Inc. Discuss Collaboration in Internet Healthcare
On November 13, 2024, Mr. Andriy Samoylovych, Chief Commercial Officer of Alfasigma Group, and Ms. Zhou Qin, General Manager of Alfasigma China, met with Dr. Xie Fangmin, Chairman and CEO of Fangzhou Inc. The meeting took place at Fangzhou’s offices in Shanghai. They discussed trends in China’s Internet healthcare and explored potential collaboration areas.
Digital Transformation in Healthcare
The rise of digital technology is transforming Internet healthcare in China. More patients are seeking online medical services for convenience and better experiences. Dr. Xie emphasized that the growth of Internet hospitals in China depends on technological advancements and the acceptance of new healthcare models by patients.
Collaborative Efforts to Improve Healthcare Services
Mr. Samoylovych and the Fangzhou team discussed improving patient access to innovative medications and the current state of Internet healthcare in China. Both companies have previously collaborated in various fields, including cardiovascular health and nephrology. The meeting underscored their shared achievements and outlined goals for future partnership to enhance Internet healthcare.
About Fangzhou Inc.
Fangzhou Inc. is a leading online chronic disease management platform in China. As of June 30, 2024, it had 45.6 million registered users and 217,000 registered doctors. Fangzhou provides medical care and precision medicine to patients with chronic diseases. More information can be found at Fangzhou’s investor page.
About Alfasigma
Alfasigma, established in Italy, operates in over 100 countries. With a legacy of more than 75 years, it focuses on research, development, and distribution of innovative therapies. The company’s products cover areas such as gastroenterology, vascular health, and rheumatology.
Media Contact
For inquiries, please contact:
Xingwei Zhao
Associate Director of Public Relations
Email: Contact Xingwei